Official site for STOBOCLO® (denosumab) from Celltrion. Find prescribing information, safety, and resources.

2025年11月20日 · Stoboclo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Each 1.0 mL single use prefilled syringe of STOBOCLO contains 60 mg denosumab, 4.7% sorbitol, 17 mM sodium acetate, 0.01% polysorbate 20, and water for injection to a pH of 5.2.

Stoboclo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients …

Stoboclo contains denosumab, a protein (monoclonal antibody) that interferes with the action of another protein, in order to treat bone loss and osteoporosis. Treatment with Stoboclo makes bone stronger …

Stoboclo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer.

STOBOCLO. STOBOCLO® (denosumab-bmwo) injection, for subcutaneous use Initial U.S. Approval: 2025 STOBOCLO® (denosumab-bmwo) is biosimilar* to PROLIA® (denosumab). WARNING: …

2025年3月14日 · Stoboclo (denosumab-bmwo) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health …

What is the most important information I should know about Stoboclo? If you receive Stoboclo, you should not receive other denosumab products at the same time. Increased risk of severe low calcium …

Stoboclo (denosumab-bmwo) injection is a clear, colorless to pale yellow solution supplied in a single-dose prefilled syringe with a safety guard. The prefilled syringe is not made with natural rubber latex.